Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sichuan Hongmingbosi Pharmaceutical is a China-based pharmaceutical company headquartered in Chengdu, specializing in the research, development, and manufacturing of innovative small molecule drugs and high-end generics. The company operates a comprehensive value chain including a dedicated R&D center and a GMP-certified manufacturing facility located in the Chengdu Medical City. Its therapeutic focus primarily spans oncology, cardiovascular health, and metabolic disorders. Hongmingbosi aims to provide affordable, high-quality medicines through its pipeline of chemical drugs and active pharmaceutical ingredients (APIs). The company is currently advancing several proprietary candidates through clinical trials while maintaining a portfolio of commercialized generic products.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Sichuan Hongmingbosi Pharmaceutical.